Data / Drug companies / Cardinal Health 107, LLC
Cardinal Health 107, LLC: 461 products in the FDA NDC directory, labeler code 55154
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Cardinal Health 107, LLC (labeler code 55154) lists 461 products in the FDA National Drug Code Directory, covering 184 finished drugs by generic name. By type: 419 prescription drugs, 42 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 7, 2026.
The request: Watch Cardinal Health 107, LLC (FDA labeler code 55154): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 55154
- Products in commercial distribution
- 461
- Packages
- 464
- Finished drugs by generic name
- 184
- Prescription products
- 419
- Over the counter products
- 42
- Controlled substance products
- Schedule III 1, Schedule IV 5, Schedule V 4
- Flagged as original packager
- 1 of 1 products that carry the flag
- Started marketing in the last 12 months
- 42
- Products with a marketing end date set
- 39
- Earliest marketing start
- April 27, 1955
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 389 | 84.4% |
| New drug applications (NDA) | 40 | 8.7% |
| Over the counter monograph drugs | 27 | 5.9% |
| Authorized generics (NDA) | 3 | 0.7% |
| Other unapproved drugs | 2 | 0.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 419 | 90.9% |
| Over the counter drugs | 42 | 9.1% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 139 | 30.2% |
| Tablet, film coated | 124 | 26.9% |
| Injection, solution | 35 | 7.6% |
| Capsule | 34 | 7.4% |
| Injection | 25 | 5.4% |
| Solution | 15 | 3.3% |
| Tablet, delayed release | 12 | 2.6% |
| Suspension | 11 | 2.4% |
| Tablet, film coated, extended release | 10 | 2.2% |
| Injection, powder, for solution | 8 | 1.7% |
| Tablet, extended release | 6 | 1.3% |
| Powder, for solution | 6 | 1.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Divalproex Sodium | 55154-0577 | Tablet, delayed release | Generic drugs (ANDA) | October 7, 2026 |
| Pantoprazole Sodium | 55154-0289 | Tablet, delayed release | Generic drugs (ANDA) | September 14, 2026 |
| Hydralazine Hydrochloride | 55154-0287 | Tablet | Generic drugs (ANDA) | September 14, 2026 |
| Mycophenolate mofetil | 55154-0161 | Capsule | Generic drugs (ANDA) | September 14, 2026 |
| Gabapentin | 55154-0581 | Capsule | Generic drugs (ANDA) | September 11, 2026 |
| Levetiracetam | 55154-0288 | Tablet, film coated | Generic drugs (ANDA) | September 11, 2026 |
| Buspirone Hydrochloride | 55154-0286 | Tablet | Generic drugs (ANDA) | September 2, 2026 |
| Buspirone Hydrochloride | 55154-0285 | Tablet | Generic drugs (ANDA) | September 2, 2026 |
| Potassium Chloride | 55154-8352 | Powder, for solution | Generic drugs (ANDA) | August 24, 2026 |
| Lansoprazole | 55154-8340 | Tablet, orally disintegrating, delayed release | Generic drugs (ANDA) | August 24, 2026 |
| Potassium chloride | 55154-8026 | Solution | Generic drugs (ANDA) | August 24, 2026 |
| Nicotine | 55154-6818 | Gum, chewing | Generic drugs (ANDA) | August 24, 2026 |
| Gabapentin | 55154-0580 | Capsule | Generic drugs (ANDA) | August 24, 2026 |
| Diphenhydramine Hydrochloride | 55154-1589 | Tablet | Over the counter monograph drugs | August 7, 2026 |
| Olanzapine | 55154-6693 | Tablet, film coated | Generic drugs (ANDA) | July 28, 2026 |
| Aspirin 81mg Enteric Coated | 55154-2607 | Tablet, delayed release | Over the counter monograph drugs | July 28, 2026 |
| Gabapentin | 55154-0579 | Capsule | Generic drugs (ANDA) | July 28, 2026 |
| Ipratropium Bromide | 55154-4411 | Solution | Generic drugs (ANDA) | July 24, 2026 |
| Atorvastatin Calcium | 55154-0284 | Tablet, film coated | Generic drugs (ANDA) | July 24, 2026 |
| Allopurinol | 55154-0282 | Tablet | Generic drugs (ANDA) | July 24, 2026 |
| Propranolol Hydrochloride | 55154-2584 | Tablet | Generic drugs (ANDA) | July 20, 2026 |
| Docusate Sodium | 55154-0578 | Capsule, liquid filled | Over the counter monograph drugs | July 20, 2026 |
| Atenolol | 55154-0283 | Tablet | Generic drugs (ANDA) | July 20, 2026 |
| Ibuprofen | 55154-2583 | Tablet | Generic drugs (ANDA) | July 10, 2026 |
| Sucralfate | 55154-0281 | Tablet | Generic drugs (ANDA) | July 10, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.